Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of menin inhibitors in the treatment of AML

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the use of menin inhibitors for the treatment of acute myeloid leukemia (AML), drawing focus on DSP-5336. Dr Daver first highlights the safety and efficacy of these agents and further comments on their role in the future treatment landscape of AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.